Biogen’s Aduhelm Suffers Disappointing Sales

Biogen has so far netted just $300,000 from the sale of Aduhelm, its controversial antiamyloid antibody, a fraction of what the company anticipated for its recently approved Alzheimer’s treatment.

Two key factors are driving the antibody’s poor sales — a delay in a federal reimbursement decision and continued misunderstanding of Aduhelm’s clinical data among clinicians and patients.

Sales of Aduhelm and any other antiamyloid antibodies approved in the future will hinge on the National Coverage Determination for the new class of drugs.

The Centers for Medicare and Medicaid Services will issue a draft National Coverage Determination in January, with a decision forthcoming by next April.